Milestone Pharmaceuticals (MIST) Competitors

Milestone Pharmaceuticals (NASDAQ:MIST) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.

Do insiders & institutionals have more ownership in MIST or RZLT?

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 18.4% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in MIST or RZLT?

Milestone Pharmaceuticals received 12 more outperform votes than Rezolute when rated by MarketBeat users. However, 79.57% of users gave Rezolute an outperform vote while only 68.25% of users gave Milestone Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Milestone Pharmaceuticals	Outperform Votes 86 68.25%	Underperform Votes 40 31.75%
Rezolute	Outperform Votes 74 79.57%	Underperform Votes 19 20.43%

Which has stronger earnings & valuation, MIST or RZLT?

Milestone Pharmaceuticals has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1M	91.96	-$59.69M	-$0.78	-2.21
Rezolute	N/A	N/A	-$68.46M	-$1.15	-3.78

Is MIST or RZLT more profitable?

Rezolute's return on equity of -70.27% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-151.82%	-49.85%
Rezolute	N/A	-70.27%	-62.41%

Does the media refer more to MIST or RZLT?

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Milestone Pharmaceuticals and 3 mentions for Rezolute. Rezolute's average media sentiment score of 1.84 beat Milestone Pharmaceuticals' score of 1.09 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts recommend MIST or RZLT?

Milestone Pharmaceuticals currently has a consensus target price of $7.00, suggesting a potential upside of 306.98%. Rezolute has a consensus target price of $11.83, suggesting a potential upside of 172.03%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rezolute	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Which has more risk and volatility, MIST or RZLT?

Milestone Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Milestone Pharmaceuticals beats Rezolute on 10 of the 17 factors compared between the two stocks.